Evidence map›Paper›PMID 30218298›Full record

ArticleClinical and experimental nephrology2019

Risk factors for kidney disease among HIV-1 positive persons in the methadone program.

Bartłomiej Matłosz, Ewa Pietraszkiewicz, Ewa Firląg-Burkacka, Ewa Grycner, Andrzej Horban, Justyna D Kowalska

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Bartłomiej MatłoszHIV Out-Patient Clinic, Hospital for Infectious Diseases, ul. Wolska 37, 01-201, Warsaw, Poland. bmatlosz@wp.pl.
Ewa PietraszkiewiczHIV Out-Patient Clinic, Hospital for Infectious Diseases, ul. Wolska 37, 01-201, Warsaw, Poland.
Ewa Firląg-BurkackaHIV Out-Patient Clinic, Hospital for Infectious Diseases, ul. Wolska 37, 01-201, Warsaw, Poland.
Ewa GrycnerHIV Out-Patient Clinic, Hospital for Infectious Diseases, ul. Wolska 37, 01-201, Warsaw, Poland.
Andrzej HorbanDepartment for Adults Infectious Diseases, Medical University of Warsaw, ul. Wolska 37, 01-201, Warsaw, Poland.
Justyna D KowalskaHIV Out-Patient Clinic, Hospital for Infectious Diseases, ul. Wolska 37, 01-201, Warsaw, Poland.
Medical University of Warsaw · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKidney injury is a serious comorbidity among HIV-infected patients. Intravenous drug use is listed as one of the risk factors for impaired renal function; however, this group is rarely assessed for specific renal-related risks.

methodsPatients attending methadone program from 1994 to 2015 were included in the study. Data collected included demographic data, laboratory tests, antiretroviral treatment history, methadone dosing and drug abstinence. Patients' drug abstinence was checked monthly on personnel demand. We have evaluated two study outcomes: (1) having at least one or (2) three eGFR < 60 ml/min (MDRD formula).

resultsIn total, 267 persons, with 2593 person-years of follow-up were included into analyses. At the time of analyses, 251 (94%) were on antiretroviral therapy (ARV). Fifty-two (19.5%) patients had 1eGFR and 20 (7.5%) 3eGFR < 60. In univariate analysis, factors significantly increasing the odds of impaired renal function were: female gender, detectable HIV RNA on ART, age at registration per 5 years older, atazanavir use and time on antiretroviral treatment per 1 year longer. In the multivariate model, only female gender (OR 4.7; p = 0.002), time on cART (OR 1.11; p = 0.01) and baseline eGFR (OR 0.71; p = 0.001) were statistically significant.

conclusionsWe have demonstrated a high rate of kidney function impairment among HIV-1 positive patients in the methadone program. All risk factors for decreased eGFR in this subpopulation of patients were similar to those described for general HIV population with very high prevalence in women. These findings imply the need for more frequent kidney function monitoring in this subgroup of patients.

Indexed as

AdultAnti-HIV AgentsAtazanavir SulfateDrug Therapy, CombinationFemaleGlomerular Filtration RateHIV InfectionsHumansIndinavirKidney DiseasesMaleMethadoneNarcoticsOpiate Substitution TreatmentOpioid-Related DisordersPolandAnti-HIV AgentsAtazanavir SulfateIndinavirMethadoneNarcoticsTenofovirChronic kidney diseaseHIVIntravenous drug useMethadone

Identifiers

PMID30218298
OpenAlexW2890907008

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.